4D Molecular Therapeutics, Inc. (FDMT) Stock Grade

About 4D Molecular Therapeutics, Inc.'s fundamentals

4D Molecular Therapeutics is a biotechnology company with a market capitalization of $434.5 million that reported a net loss in its latest annual statement, resulting in a negative net margin of -164.4%. The company showed exceptional revenue growth of 230,194.6% year-over-year, though this dramatic increase from a very small revenue base is typical of early-stage biotech firms scaling operations. The company does not pay a dividend and does not have meaningful profitability metrics such as a P/E ratio or return on equity, reflecting its current stage of development as it advances its therapeutic pipeline.